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ABSTRACT
Background: Cough and sputum are troublesome
symptoms in chronic obstructive pulmonary disease
(COPD) and are associated with adverse outcomes.
The efficacy of aclidinium bromide 400 µg twice daily
in patients with stable COPD has been established in
two phase III studies (ACCORD COPD I and ATTAIN)
and a phase IIIb active-comparator study. This analysis
evaluated cough-related symptoms across these
studies.
Method: Patients were randomised to placebo,
aclidinium 200 µg or 400 µg twice daily in ACCORD
(12 weeks) and ATTAIN (24 weeks), or to placebo,
aclidinium 400 µg twice daily or tiotropium 18 µg once
daily (6-week active-comparator study). Analysed end
points included changes from baseline in Evaluating
Respiratory Symptoms (E-RS; formerly known as
EXAcerbations of Chronic pulmonary disease Tool),
total and cough/sputum scores and frequency/severity
of morning and night-time cough and sputum
symptoms.
Results: Data for 1792 patients were evaluated. E-RS
cough/sputum domain scores were significantly
reduced with aclidinium 400 µg versus placebo in
ATTAIN (−0.7 vs −0.3, respectively; p<0.01) and the
active-comparator study (−0.6 vs −0.2, respectively;
p<0.01). In the active-comparator study, significantly
greater improvements were observed with aclidinium
versus placebo for severity of morning cough (−0.19
vs −0.02; p<0.01) and phlegm (−0.19 vs −0.02;
p<0.05). In ACCORD, aclidinium reduced night-time
cough frequency (−0.36 vs 0.1 for placebo; p<0.001)
and severity (−0.24 vs −0.1 for placebo; p<0.05), and
frequency of night-time sputum production (−0.37 vs
0.05 for placebo; p<0.001).
Conclusions: Aclidinium 400 µg twice daily improves
cough and sputum expectoration versus placebo in
stable COPD.
Trial registration numbers: NCT00891462;
NCT01001494; NCT01462929.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is characterised by persistent and
progressive airﬂow limitation and an
enhanced inﬂammatory response to noxious
stimuli.1 The resulting lung injury leads to
breathlessness and other characteristic symp-
toms of COPD, including cough and sputum.
In patients with COPD, chronic cough and
sputum production are associated with lung-
function decline,2 more frequent exacerba-
tions and hospitalisations, and increased risk
of death.3 4 Accumulation of mucus in small
airways is also associated with disease progres-
sion,5 and a productive cough has been shown
to be independently associated with increased
mortality in smokers with mild-to-moderate
airﬂow obstruction.6 Cough symptoms also
impact adversely on the health status of
patients with COPD to a similar degree to that
observed in bronchiectasis, asthma and
chronic cough.7 The importance of cough
and sputum symptoms in deﬁning a patient’s
overall well-being is reﬂected in the inclusion
of these items in the COPD Assessment Test, a
patient-reported outcomes tool designed to
assess overall COPD-related health status.8 9
Between disease exacerbations, when
COPD is considered stable, there may still be
KEY MESSAGES
▸ Cough and sputum in COPD have a substantial
impact on patients’ health status, yet there are
relatively few studies that have investigated the
effect of bronchodilators on these symptoms.
▸ In this paper, we analyse data from three Phase
III studies to elucidate the effect of aclidinium
bromide on cough and sputum. The results
suggest that in addition to improving lung func-
tion, LAMAs, such as aclidinium, can improve
cough and sputum expectoration compared with
placebo in patients with COPD.
▸ As cough and sputum impact negatively on
overall patient wellbeing, controlling these symp-
toms may represent an important additional
therapeutic benefit of this class of drugs.
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Chronic obstructive pulmonary disease
marked daily variability in patients’ perceptions of
symptom severity. In a pan-European cross-sectional
study in patients with COPD, cough and phlegm were
reported to be most troublesome in the morning.10
However, in a recent observational study of COPD symp-
toms, despite overall night-time symptoms being less
prevalent than in the morning and during the day,
cough was still the most common symptom at night.11
Despite the evidence of a clear association between
cough and adverse clinical outcomes, its signiﬁcance in
patients with COPD is often underappreciated.12 13 In add-
ition, almost nothing is known about the effect of current
ﬁrst-line COPD treatments on symptoms of cough and
sputum, and the need for studies to address this has been
highlighted.12 Aclidinium bromide is a long-acting muscar-
inic antagonist (LAMA) that inhibits the action of acetyl-
choline at M3 receptors in the lungs, indirectly leading to
airway smooth muscle relaxation. Aclidinium is approved
as a maintenance bronchodilator treatment in patients
with COPD.14–16 Several phase III studies have shown that
aclidinium 400 µg twice daily improves lung function and
symptoms in patients with moderate-to-severe airﬂow limi-
tation.17–23 In this manuscript, we report our analysis of
the data from three of these studies, ACCORD COPD I,
ATTAIN and a 6-week active-comparator study, which was
undertaken to determine the effect of the approved
dose of aclidinium (400 µg twice daily metered dose;
equivalent to aclidinium 322 μg delivered dose) on cough
and sputum symptoms in patients with stable
moderate-to-severe COPD. The three phase III studies
reported here were selected on the basis that they had
similar inclusion/exclusion criteria and included end
points that assessed the efﬁcacy of aclidinium 400 µg twice
daily on cough and sputum symptoms. Four additional
phase III studies of aclidinium did not record cough data
so could not be included in this analysis.
METHODS
In these analyses, only data from patients randomised to
placebo, aclidinium 400 µg twice daily (the dose approved
for use in patients with COPD) or tiotropium 18 µg once
daily (also the approved dose) were evaluated. The purpose
of this additional analysis was to assess the impact of aclidi-
nium on cough and sputum symptoms across three clinical
studies, including the relationship between symptoms and
time of day. All end points were preplanned, with the excep-
tion of post hoc analyses assessing the correlation between
Evaluating Respiratory Symptoms (E-RS; formerly known as
EXAcerbations of Chronic pulmonary disease Tool) cough
and sputum domain score and cough severity score in the
active-comparator study and change from baseline in E-RS
total and cough and sputum domain scores in patients who
had ≥1 exacerbation event in the ATTAIN study.
Study design
ACCORD COPD I (ClinicalTrials.gov identiﬁer:
NCT00891462) and ATTAIN (ClinicalTrials.gov
identiﬁer: NCT01001494) were multinational, rando-
mised, double-blind, placebo-controlled phase III
studies.17 18 Following screening and a 2-week run-in
period, patients were randomised (1:1:1) to receive acli-
dinium 200 µg, aclidinium 400 µg (metered dose;
equivalent to aclidinium 322 µg delivered dose) or
placebo twice daily via the Genuair™/Pressair®i inhaler
for 12 weeks in ACCORD COPD I and 24 weeks in
ATTAIN.
The third study was a randomised, double-blind,
double-dummy, placebo-controlled and active-controlled
phase IIIb study (ClinicalTrials.gov identiﬁer:
NCT01462929).19 Following a 2–3-week run-in period,
patients were randomised (2:2:1) to receive aclidinium
400 µg twice daily (metered dose; equivalent to aclidi-
nium 322 µg delivered dose), tiotropium 18 µg once
daily in the morning via HandiHaler® or placebo for
6 weeks.
In all three studies, inhaled albuterol/salbutamol
(108/100 µg/puff) was permitted as relief medication as
long as it was discontinued 6 hours prior to study visits.
Additional permitted medications included inhaled cor-
ticosteroids, oral or parenteral corticosteroids (≤10 mg/
day of prednisone or 20 mg every other day), oral
sustained-release theophyllines and oxygen therapy
(<15 hours/day), provided that treatment was stable for
≥4 weeks before screening. Other long-acting broncho-
dilators and anticholinergic drugs were washed out prior
to screening and were not allowed during the treatment
periods.
All studies were conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonisation/Good Clinical Practice Guidelines and
local regulations. The protocols were approved by insti-
tutional review boards/independent ethics committees
at each site, and all patients gave written informed
consent.
Study populations
Detailed inclusion/exclusion criteria for the three
studies have been reported previously.17–19 Brieﬂy, each
study enrolled male and female patients (≥40 years old)
with a diagnosis of stable COPD and moderate-to-severe
airﬂow obstruction (postbronchodilator forced expira-
tory volume in 1 s (FEV1) ≥30% and <80% of the pre-
dicted value and FEV1/forced vital capacity ratio <70%)
1
who were current or former smokers with a smoking
history of ≥10 pack-years. The presence of cough or
sputum symptoms at baseline was not a speciﬁc inclusion
criterion in any of the studies.
Exclusion criteria included any respiratory tract infec-
tion or COPD exacerbation within 6 weeks prior to
screening (3 months if exacerbation resulted in
iRegistered trademarks of AstraZeneca group of companies; for use
within the USA as Pressair® and GenuairTM within all other licensed
territories.
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hospitalisation), any clinically relevant respiratory condi-
tions, including a history or current diagnosis of asthma
and a history of hypersensitivity to inhaled anticholiner-
gics or other inhaled medications.
Study assessments
A summary of patient-reported outcome measures used
to capture symptoms in each clinical trial and corre-
sponding end points are shown in online supplementary
table S1. Baseline values for all end points were calcu-
lated as the average scores over the 2–3-week screening
period prior to randomisation.
Daily symptoms
In ATTAIN and the active-comparator study, daily
respiratory symptoms were assessed using the E-RS algo-
rithm.24–26 The EXACT is a 14-item electronic daily
diary used to quantify and measure exacerbations of
COPD. It is completed by patients at night with a recall
period of ‘today’ and captures symptoms of COPD
including cough and sputum production. The E-RS total
score (range 0–40) is a derivative tool which uses the
11 EXACT items that relate speciﬁcally to respiratory
symptoms, with higher scores indicating more severe
symptoms; the E-RS cough and sputum domain score is
the sum of the three EXACT items that relate speciﬁc-
ally to cough and sputum symptoms (range 0–11).
Responder criteria for E-RS total score and E-RS cough
and sputum domain scores have been proposed as a
change of ≥−2.0 units in the E-RS total score and ≥−0.7
in the E-RS cough and sputum domain score.27 The
E-RS was not used in the ACCORD study.
Morning and night-time cough and sputum symptoms
Cough and sputum symptoms during the morning and
night-time were assessed in the three phase III studies
using questionnaires developed by the study spon-
sors.28 29 In ATTAIN, a 6-item night-time and morning
symptoms of COPD questionnaire, completed by
patients at approximately the same time every morning
using an electronic patient diary, was used to assess the
number of days patients experienced a range of
morning or night-time symptoms, including coughing
and bringing up phlegm or mucus. The questionnaire
included one item that asked patients if they experi-
enced symptoms during the night and one item that
asked about their symptoms since they got out of bed to
start the day.
In the active-comparator study, morning symptoms
were assessed using a 9-item COPD symptom question-
naire, completed daily by patients between 7:00 am and
11:00 am using an electronic diary. Early morning was
deﬁned as the time from when patients got out of bed
to start the day until they started their daily activities.
One item of the questionnaire was related to the pres-
ence of a range of early-morning symptoms, including
cough and phlegm, with ﬁve items related to the severity
of these symptoms. Patients assessed the severity of their
overall morning symptoms (5-point scale: 1=‘I did not
experience any symptoms’; 2=‘mild’; 3=‘moderate’;
4=‘severe’; 5=‘very severe’) and the severity of individual
symptoms, including cough and difﬁculty bringing up
phlegm (5-point scale: 0=‘no symptoms’; 1=‘mild’;
2=‘moderate’; 3=‘severe’; 4=‘very severe’).
In ACCORD COPD I, night-time symptoms were
assessed using an 11-item COPD night-time symptoms
questionnaire, adapted from an existing COPD symptom
questionnaire30 to include additional items assessing the
frequency of COPD symptoms, such as night-time
breathlessness, cough, sputum production and wheez-
ing, during the previous night. Patients completed the
questionnaire daily in the morning using an electronic
patient diary (the recall period was ≤24 hours). The fre-
quency of night-time symptoms was assessed on a 5-point
scale: 0=‘never’; 1=‘1–2 times’; 2=‘3–4 times’; 3=‘5–6
times’; 4=‘7 or more times’. The severity and impact of
night-time symptoms were assessed on a 5-point scale:
0=‘no symptoms’; 1=‘symptoms present but caused
little/no discomfort’; 2=‘mild symptoms that were
unpleasant but caused little/no discomfort’; 3=‘moder-
ate symptoms that caused discomfort but did not affect
daily activities’; 4=‘severe symptoms that interfered with
normal daily activities’.
End points
Predeﬁned efﬁcacy end points included: changes from
baseline in E-RS total score and E-RS cough and sputum
domain score over the study period (ATTAIN and active-
comparator study); the percentage of days with morning
or night-time symptoms over the study period
(ATTAIN); changes from baseline in the percentage of
days without morning symptoms and the severity of
morning cough and difﬁculty bringing up phlegm over
the study period (active-comparator study) and changes
from baseline at week 12 in COPD night-time symptoms
(ACCORD COPD I). To investigate the reliability of dif-
ferent measures of cough symptoms used in these ana-
lyses, a post hoc analysis assessed the correlation
between changes from baseline in E-RS cough and
sputum domain scores in those patients who had
≥1 exacerbation event in the ATTAIN study, and the
severity of morning cough (based on the symptom ques-
tionnaires) at week 6 in the active-comparator study.
These were selected as both measures assess the
improvement from baseline in symptom severity.
Safety and tolerability were assessed in all three studies
by recording adverse events. Additional safety assess-
ments included a physical examination, laboratory tests,
vital signs and ECGs.
Statistical analyses
Demographic and baseline characteristics were assessed
in the intent-to-treat (ITT) population (all treated
patients who had baseline and at least one postbaseline
FEV1 assessment) and are reported as mean (SD) or
percentage, as appropriate. Efﬁcacy analyses were
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performed in the ITT population. Changes from base-
line in E-RS total and cough and sputum domain scores
(ATTAIN and active-comparator study), percentage of
days with morning or night-time cough symptoms
(ATTAIN) and changes from baseline in the percentage
of days without morning symptoms and the severity of
morning symptoms (active-comparator study) were ana-
lysed using an analysis of covariance (ANCOVA) model,
with treatment group and sex as factors and age and
corresponding baseline as covariates. Changes from
baseline in the frequency and severity of night-time
symptoms (ACCORD COPD I) were analysed using an
ANCOVA model with treatment as a factor and the cor-
responding baseline as a covariate. Data are reported as
least squares mean (SEM), least squares mean differ-
ences (95% CIs) or percentages, as appropriate. For the
post hoc analysis, Pearson coefﬁcients were used to
evaluate the correlation between improvements in E-RS
cough and sputum domain score and the scores from
the cough severity question in symptom questionnaires.
Additional post hoc analyses assessed the change
from baseline in E-RS total and cough and sputum
domain scores in those patients who had ≥1 exacerba-
tion event identiﬁed using the EXACT in the ATTAIN
study. An EXACT-identiﬁed event was deﬁned as a
persistent increase from baseline in total EXACT
score of ≥9 points for ≥3 days or ≥12 points for
≥2 days.26 31
RESULTS
Patient population
The ITT populations in ACCORD COPD I, ATTAIN
and the active-comparator study included 559, 819 and
414 patients, respectively. Demographics and baseline
clinical characteristics of the study populations have
been reported previously;17–19 the demographics and
baseline clinical characteristics in the placebo, aclidi-
nium 400 μg and tiotropium arms are shown in table 1.
E-RS scores and symptom questionnaire scores at base-
line in the placebo, aclidinium 400 μg and tiotropium
study arms are shown in online supplementary
table S2.
Safety and tolerability
Safety and tolerability outcomes have previously been
reported for each study.17–19 In summary, aclidinium is
well tolerated with the most common adverse events
being nasopharyngitis, headache, COPD exacerbation
and cough. No clinically signiﬁcant differences in other
safety assessments were observed. No new safety and tol-
erability ﬁndings were anticipated based on these add-
itional analyses.
Daily COPD symptoms
Treatment with aclidinium 400 µg signiﬁcantly reduced
total daily COPD symptoms compared with placebo, as
assessed by E-RS total score over 24 weeks in ATTAIN
Table 1 Demographics and baseline clinical characteristics (ITT population)
ACCORD COPD I ATTAIN Active-comparator study
Characteristic
Placebo
(N=185)
Aclidinium
400 µg
twice daily
(N=190)
Placebo
(N=273)
Aclidinium
400 µg
twice daily
(N=269)
Placebo
(N=85)
Aclidinium
400 µg
twice daily
(N=171)
Tiotropium
18 µg once
daily
(N=158)
Age (years), mean (SD) 65.0 (9.2) 64.9 (9.5) 62.0 (8.0) 62.9 (8.4) 62.2 (8.2) 61.8 (8.2) 62.8 (7.9)
Gender (male), n (%) 95 (51.4) 100 (52.6) 189 (69.2) 182 (67.7) 48 (56.5) 114 (66.7) 116 (73.4)
Current smoker, n (%) 87 (47.0) 80 (42.1) 144 (52.8) 148 (55.0) 47 (55.3) 93 (54.4) 84 (53.2)
Smoking history (pack-years),
mean (SD)
52.9 (28.1) 57.2 (28.5) 38.9 (18.3) 41.7 (21.1) 39.6 (15.4) 41.5 (22.4) 45.0 (21.8)
Postbronchodilator FEV1,* mean
(SD), L
1.6 (0.6) 1.5 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.7 (0.5)
Postbronchodilator FEV1%
predicted,*
mean (SD)
54.7 (13.4) 54.1 (12.9) 56.6 (12.8) 56.2 (12.2) 55.5 (11.8) 55.8 (13.3) 56.0 (13.2)
Severity of airflow limitation,†,‡ n (%)
Moderate 111 (60.0) 118 (62.1) 178 (65.9) 184 (68.7) 58 (68.2) 108 (63.2) 104 (66.2)
Severe 72 (38.9) 68 (35.8) 92 (34.1) 84 (31.3) 27 (31.8) 63 (36.8) 53 (33.8)
≥1 COPD exacerbation in
previous year,‡
n (%)
52 (28.1) 43 (22.6) 88 (32.6) 97 (36.2) 19 (22.4) 61 (35.7) 47 (29.7)
Concomitant use of ICS, n (%) 70 (37.6) 81 (42.6) 145 (53.1) 128 (47.6) 36 (42.4) 82 (48.0) 67 (42.4)
*At screening visit.
†Moderate COPD: 50% ≤postbronchodilator FEV1 <80% predicted and FEV1/FVC <0.70; severe COPD: 30% ≤postbronchodilator FEV1
<50% predicted and FEV1/FVC <0.70.
‡Patients with available data.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid;
ITT, intent-to-treat.
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(p<0.001; ﬁgure 1A) and 6 weeks in the active-
comparator study (p<0.001; ﬁgure 1A).19 In the active-
comparator study, E-RS total score was also signiﬁcantly
reduced with tiotropium compared with placebo
(p<0.05; ﬁgure 1A).
Daily cough and sputum symptoms, assessed by E-RS
cough and sputum domain score, were also signiﬁcantly
reduced with aclidinium 400 µg versus placebo in
ATTAIN and the active-comparator study (both p<0.01;
ﬁgure 1B). There was no signiﬁcant difference between
tiotropium and placebo treatments on cough and
sputum symptoms in the active-comparator study
(p=0.109; ﬁgure 1B).
Post hoc analysis of a patient subpopulation with
≥1 exacerbation event identiﬁed by the EXACT
(n=178) indicated that E-RS total score and E-RS cough
and sputum scores were similar at baseline between
aclidinium 400 μg and placebo in ATTAIN. After
24 weeks, treatment differences (95% CI) between acli-
dinium 400 μg and placebo in this group were signiﬁ-
cant for E-RS total score (−1.9 [−3.1 to −0.6]; p<0.01)
and E-RS cough and sputum scores (−0.5 [−0.9 to
−0.2]; p<0.01).
Morning and night-time cough and sputum symptoms
In ATTAIN, the percentage of days with any morning or
night-time symptoms over the study period was signiﬁ-
cantly lower in patients treated with aclidinium 400 µg
compared with placebo (both p<0.001; ﬁgure 2).
Aclidinium treatment also signiﬁcantly reduced the per-
centage of days with morning or night-time cough symp-
toms compared with placebo (both p<0.01; ﬁgure 2).
Similarly, the percentage of days with morning or night-
time bringing up phlegm or mucus was also signiﬁcantly
lower over the study period in patients treated with aclidi-
nium 400 µg compared with placebo (p<0.01; ﬁgure 2).
In the active-comparator study, both aclidinium and
tiotropium signiﬁcantly increased the change from base-
line in the percentage of days without any morning
symptoms over the study period versus placebo (treat-
ment differences [95% CI] 8.9% [4.1% to 13.8%] with
aclidinium and 5.6% [0.6% to 10.6%] with tiotropium;
p<0.001 and p<0.05 vs placebo, respectively). Similarly,
there was a signiﬁcant increase in the percentage of days
without morning cough symptoms in the aclidinium
group compared with placebo (treatment difference
[95% CI] 7.2% [1.1% to 13.4%]; p<0.05); there was no
Figure 1 Change from baseline
in (A) E-RS total score and (B)
E-RS cough and sputum domain
score over the study period in
ATTAIN and the
active-comparator study.
Data are reported as LS mean
+SE. E-RS total score ranged
from 0 to 40; E-RS cough and
sputum domain score ranged
from 0 to 11. Higher scores
indicate more severe symptoms.
*p<0.05, **p<0.01, ***p<0.001 vs
placebo. E-RS, Evaluating
Respiratory Symptoms, formerly
known as EXAcerbations of
Chronic pulmonary disease Tool;
LS, least squares; MCID,
minimum clinically important
difference.
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signiﬁcant difference with tiotropium versus placebo
(treatment difference [95% CI] 5.5% [−0.8% to
11.8%]; p=0.084). While the change from baseline in
the percentage of days without difﬁculty bringing up
phlegm was numerically higher with aclidinium (7.7%)
and tiotropium (4.8%) compared with placebo (2.0%),
the differences between the active treatments and
placebo did not reach statistical signiﬁcance (p=0.100
for aclidinium and p=0.425 for tiotropium).
Patients’ assessment of the overall severity of their
morning symptoms over the study duration was signiﬁ-
cantly reduced with aclidinium (−0.22; p<0.001) and tio-
tropium (−0.12; p<0.05) compared with placebo in the
active-comparator study.19 When the severity of morning
cough and difﬁculty bringing up phlegm was assessed,
there was a signiﬁcant reduction in the severity of both
symptoms with aclidinium versus placebo over 6 weeks
(p<0.05; ﬁgure 3). There was no signiﬁcant change
from baseline in the severity of either cough or difﬁculty
bringing up phlegm in patients treated with tiotropium
compared with placebo.
ACCORD COPD I investigated the prevalence and
severity of night-time cough and sputum symptoms.17
After 12 weeks of treatment, aclidinium 400 µg signiﬁ-
cantly reduced the frequency of night-time cough com-
pared with placebo (p<0.001; ﬁgure 4). The severity and
impact of night-time cough symptoms was also signiﬁ-
cantly reduced at week 12 with aclidinium 400 µg com-
pared with placebo (p<0.05; ﬁgure 4). In addition, the
frequency of night-time sputum production was signiﬁ-
cantly lower in patients treated with aclidinium 400 µg
compared with placebo (p<0.001; ﬁgure 4).
Correlation between E-RS and symptom questionnaires
When all treatment groups were combined, there was
signiﬁcant correlation between the improvement in E-RS
cough and sputum domain score and the improvement
in the severity of morning cough symptoms assessed
using the symptom questionnaire (r=0.684; p<0.001).
Similar results were observed when the correlation
between scores was assessed in each active treatment
group (data not shown).
DISCUSSION
This analysis is the ﬁrst to speciﬁcally investigate the
impact of a LAMA, or indeed any bronchodilator, on
cough and sputum symptoms in patients with stable
moderate-to-severe COPD. The results of the ATTAIN,
Figure 2 Percentage of days with (A) morning symptoms
and (B) night-time symptoms over the study period in
ATTAIN. Data are reported as least squares mean.
**p<0.01, ***p<0.001 vs placebo.
Figure 3 Change from baseline
in the severity of morning cough
and severity of difficulty bringing
up phlegm in the morning over
the study period in the
active-comparator study. Data are
reported as LS mean+SE.
Assessed on a 5-point scale:
0=‘no symptoms’ to 4=‘very
severe symptoms’. *p<0.05,
**p<0.01 vs placebo. LS, least
squares.
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ACCORD COPD I and active-comparator studies provide
evidence that aclidinium is effective at reducing the
severity and frequency of cough and sputum symptoms
in patients with COPD, with improvements in E-RS total
and E-RS cough and sputum scores as well as in evalua-
tions of morning and night-time symptoms. These
improvements were seen throughout the day and irre-
spective of the assessment tools used. Furthermore, acli-
dinium has previously been shown to be well tolerated
in patients with COPD.17–19 23
Chronic cough and mucus accumulation in the
airways are strongly associated with disease progression,
lung-function decline and risk of adverse outcomes in
patients with COPD.2–4 However, most clinical trials
designed to evaluate the efﬁcacy of COPD treatments
have focused on improvements in lung function and
breathlessness and reductions in exacerbation risk as
clinical outcomes. The few trials that have assessed the
efﬁcacy of a LAMA on cough and sputum symptoms to
date have reported negative results. In phase III studies,
there was no signiﬁcant difference in physicians’ assess-
ment of cough symptoms between patients receiving tio-
tropium and those receiving placebo.32 33 Furthermore,
no effect on mucociliary clearance was observed with
ipratropium or tiotropium in patients with COPD.34 35
In contrast, patients with severe COPD treated with an
inhaled corticosteroid (ﬂuticasone) and a long-acting
β2-agonist (salmeterol) have been shown to report sig-
niﬁcantly reduced cough symptoms versus placebo.36
Before the current analysis, only smoking cessation has
consistently been shown to reduce cough and phlegm
symptoms in patients with COPD.37 38
Patients with COPD report variability in the frequency
and severity of cough and sputum symptoms throughout
the day, with greatest impact ﬁrst thing in the morning
and at night-time.10 11 39 The prevalence and severity of
cough symptoms at the start of the day may relate to
periods of increased activity associated with getting
washed and dressed, whereas the night-time cough and
sputum symptoms may be a consequence of mucus
hypersecretion or reduced ciliary activity. In the analyses
reported here, treatment with aclidinium signiﬁcantly
reduced the percentage of days and nights with symp-
toms of coughing and bringing up phlegm or mucus.
The severity of morning and night-time cough and
sputum symptoms was also found to be reduced.
Treatment approaches that impact on cough and
sputum symptoms throughout the whole 24-hour day
may provide clinical beneﬁts to some patients in terms
of their overall well-being, particularly in the morning
and night-time when patients report that these symp-
toms are most troublesome.
In the active-comparator study, while both LAMAs had
an effect, the magnitude of improvement in overall
symptoms and cough and sputum symptoms was greater
with aclidinium compared with tiotropium. The reasons
for this are unclear; however, the fact that both LAMAs
improved symptoms of cough and sputum suggests that
these may be class effects. Precisely how these com-
pounds might exert an effect on cough and sputum is
unclear, but there is an emerging body of preclinical evi-
dence suggesting that multiple pathways may be
involved. For example, there is evidence that muscar-
inic antagonists reduce experimental cough,40 and that
tiotropium and ipratropium act on TRPV1 to reduce
the cough response in preclinical models.41 In add-
ition, a 2016 preclinical study in rabbits showed that,
further to their anticholinergic activity and any action
on TRPV1 receptors, aclidinium and tiotropium may
also have antitussive actions involving mechanorecep-
tors and acid-sensing ion channels.42 These studies
provide preclinical evidence of LAMA antitussive
Figure 4 Change from baseline
in the severity of night-time cough
and the frequency of night-time
sputum production at week 12 in
ACCORD COPD I.17 Data are
reported as mean+SE. Symptom
frequency assessed on a 5-point
scale: 0=‘never’ to 4=‘7 or more
times’. Symptom severity
assessed on a 5-point scale:
0=‘no symptoms’ to 4=‘severe
symptoms that interfered with
normal daily activities’. *p<0.05,
***p<0.001 vs placebo.
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activity; however, it is not yet clear how this may trans-
late into clinical practice.
Studies of capsaicin responsiveness suggested an
increased cough reﬂex in patients with COPD;43
however, a recent study which evaluated predictors of
cough frequency found no signiﬁcant relationship
between cough frequency and capsaicin cough reﬂex
sensitivity.39 In contrast, cough frequency was independ-
ently associated with being a current smoker, smoking
history, sputum production and neutrophilic inﬂamma-
tion.39 A recent study has demonstrated that M3 recep-
tors may play a proinﬂammatory role in cigarette
smoke-induced inﬂammation in animal models of
COPD, suggesting another potential mechanism by
which LAMAs may improve cough in patients with
COPD.44 This is further supported by preclinical studies
that have shown LAMAs can reduce neutrophils and
inﬂammatory mediators, such as interleukin-6, tumour
necrosis factor-α and interferon-γ, in cigarette
smoke-exposed animal models.45 46 The efﬁcacy of
LAMAs to improve cough and sputum symptoms
requires further investigation to determine if the effects
observed with aclidinium are also seen with other drugs
in this class.
The E-RS and night-time symptoms of COPD question-
naires are validated tools for assessing cough and
sputum symptoms in patients with COPD.24 28 The
observed improvements in E-RS cough and sputum
symptoms with aclidinium 400 µg in ATTAIN
(0.7 decrease from baseline in 24 weeks) and the active-
comparator study (0.6 decrease from baseline in
6 weeks) compare well with the recently proposed
minimum clinically important difference (MCID) of
≥0.7 decrease from baseline.47 The lack of a validated
MCID in the other tools used in these studies may be
considered to be a potential limitation of this analysis.
However, the signiﬁcant correlation between improve-
ments from baseline in E-RS cough scores and the sever-
ity of morning cough symptoms assessed using symptom
questionnaires in the active-comparator study supports
the clinical utility of these tools to assess cough
symptoms.
This study has other potential limitations. It should be
stated that none of the three phase III studies reported
here was powered to detect differences in cough and
sputum symptoms, and the studies were not speciﬁcally
designed to assess these symptoms. Furthermore, there
was no prespeciﬁed minimum level of symptoms in any
of the studies, meaning the population was relatively het-
erogeneous in terms of symptoms. Clinical trials
designed speciﬁcally to assess the effects of treatments
on cough and sputum symptoms in patients with COPD,
using a combination of patient-reported outcomes,
cough-speciﬁc quality-of-life measures and objective
measures of cough and sputum symptoms, are needed
to fully understand the efﬁcacy of novel treatments on
these symptoms.
CONCLUSIONS
While few studies have investigated the effect of bronch-
odilators on cough and sputum symptoms, the results
reported here suggest that in addition to improving lung
function, LAMAs, such as aclidinium, can improve
cough and sputum expectoration compared with
placebo in patients with COPD. As cough and sputum
symptoms impact negatively on overall patient well-
being, controlling these symptoms may represent an
important additional therapeutic beneﬁt of this class of
drugs.
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